The Journal of Clinical Investigation (Jul 2022)

Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma

  • Patrick C. Lee,
  • Susan Klaeger,
  • Phuong M. Le,
  • Keegan Korthauer,
  • Jingwei Cheng,
  • Varsha Ananthapadmanabhan,
  • Thomas C. Frost,
  • Jonathan D. Stevens,
  • Alan Y.L. Wong,
  • J. Bryan Iorgulescu,
  • Anna Y. Tarren,
  • Vipheaviny A. Chea,
  • Isabel P. Carulli,
  • Camilla K. Lemvigh,
  • Christina B. Pedersen,
  • Ashley K. Gartin,
  • Siranush Sarkizova,
  • Kyle T. Wright,
  • Letitia W. Li,
  • Jason Nomburg,
  • Shuqiang Li,
  • Teddy Huang,
  • Xiaoxi Liu,
  • Lucas Pomerance,
  • Laura M. Doherty,
  • Annie M. Apffel,
  • Luke J. Wallace,
  • Suzanna Rachimi,
  • Kristen D. Felt,
  • Jacquelyn O. Wolff,
  • Elizabeth Witten,
  • Wandi Zhang,
  • Donna Neuberg,
  • William J. Lane,
  • Guanglan Zhang,
  • Lars R. Olsen,
  • Manisha Thakuria,
  • Scott J. Rodig,
  • Karl R. Clauser,
  • Gabriel J. Starrett,
  • John G. Doench,
  • Sara J. Buhrlage,
  • Steven A. Carr,
  • James A. DeCaprio,
  • Catherine J. Wu,
  • Derin B. Keskin

Journal volume & issue
Vol. 132, no. 13

Abstract

Read online

Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.

Keywords